| Vol. 22.15 – 26 April, 2021 |
| |
|
|
| Scientists present the composite outcomes of two pilot clinical trials of T cells bearing a 4-1BB-based, CD22-targeting CAR in patients with relapsed or refractory acute lymphoblastic leukemia. [Nature Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that the release, through the implantation of a hyaluronic acid hydrogel, of CAR-T cells targeting the human chondroitin sulfate proteoglycan 4, polymer nanoparticles encapsulating the cytokine interleukin-15 and platelets conjugated with the checkpoint inhibitor programmed death-ligand 1 into the tumor cavity of mice with a resected subcutaneous melanoma tumour inhibits the local recurrence of the tumor. [Nature Biomedical Engineering] |
|
|
|
| The authors characterized the cellular properties and in vivo tissue repair activity of glial enriched progenitor cells differentiated from human-induced pluripotent stem cells. [Science Translational Medicine] |
|
|
|
| Scientists demonstrated successful genome editing in primary human islets using CRISPR and Cas9. They established a paradigm for genetic studies in human islet cells, and revealed regulatory and genetic mechanisms linking non-coding variants to human diabetes risk. [Nature Communications] |
|
|
|
| Investigators established a highly specific chimeric antigen receptors (CAR) against CD44v6 on head and neck squamous cell carcinoma cells that could be expressed on normal T-cells with lentiviral vectors. [Oral Oncology] |
|
|
|
| The authors showed restoration of visual function after transplantation of purified human pluripotent stem cell-derived cones into a mouse model of advanced degeneration. [Cell Reports] |
|
|
|
| Scientists investigated the therapeutic efficacy of mesenchymal stem cells for bronchopulmonary dysplasia in premature infants. |
|
|
|
| Researchers demonstrated that the established lacrimal gland (LG) organoids resembled the characteristics of normal LG tissue and may be used as a therapy for patients with dry eye disease. [Stem Cell Research & Therapy] |
|
|
|
| Investigators compared extracellular vesicles derived from multiple human mesenchymal stem cell and cardiosphere-derived cell donors using diverse in vitro and in vivo assays. [Scientific Reports] |
|
|
|
| Gene-edited SCD CD34+ cells contributed corrected cells 6 months post-xenograft mouse transplant without off-target δ-globin editing. [Cell Reports Medicine] |
|
|
|
|
| The authors discuss existing barriers and strategies to overcome them for successful T cell expansion and persistence in the context of adoptive T cell immunotherapy for solid cancers. [Nature Reviews Immunology] |
|
|
|
| Scientists provide an overview of the use of NK cells in cancer immunotherapy, their current status in clinical trials, as well as the design and implementation of delivery technologies. [Cancer Gene Therapy] |
|
|
|
|
| Vertex Pharmaceuticals, Inc. and Obsidian Therapeutics announced that the two companies have entered into a strategic research collaboration and licensing agreement focused on the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. [Vertex Pharmaceuticals, Inc.] |
|
|
|
| LEXEO Therapeutics announced that the FDA has granted Fast Track designation to LX1001, the company’s adeno-associated virus mediated gene therapy program, for the potential treatment of apolipoprotein E4 associated Alzheimer’s disease. [LEXEO Therapeutics] |
|
|
|
|
|
|
|
| LSU Health Science Center – Shreveport, Louisianam United States |
|
|
|
| Rutgers University – New Brunswick, New Jersey, United States |
|
|
|
| NIH National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States |
|
|
|
| The University of Iowa – Iowa City, Iowa, United States |
|
|
|
| University of Washington – Seattle, Washington, United States |
|
|
|
|